不同剂量阿托伐他汀治疗冠心病伴颈动脉斑块患者的疗效和安全性评估

目的评价不同剂量阿托伐他汀治疗冠心病伴颈动脉斑块患者的疗效和安全性。方法选择2010年1月-2011年3月在涞源县医院治疗的冠心病伴颈动脉斑块患者81例,按照随机数字表法分为观察组和对照组,对照组40例给予阿托伐他汀10 mg/d治疗,观察组41例给予阿托伐他汀20 mg/d治疗,观察比较两组的疗效及安全性。结果治疗后两组患者的总胆固醇（TC）、甘油三酯（TG）、低密度脂蛋白胆固醇（LDL-C）均明显降低,观察组降低更为明显,组间差异有统计学意义（P〈0.05）;治疗后两组患者的颈总动脉内膜-中层厚度（IMT）、斑块面积明显缩小,以观察组变化更为明显,组间差异有统计学意义（P〈0.05）;两组均无严重不良反应发生。结论阿托伐他汀20 mg/d治疗冠心病伴颈动脉斑块患者的临床疗效更佳,能够明显改善患者的血脂水平、缩小颈动脉粥样斑块,并且安全性高,是首选的治疗方案之一。

Evaluation on Efficacv and Safetv of Different Doses of Atorvastatin in Treatment of Patients with Coronary Heart Disease and Carotid Plaque

Objective To assess the therapeutic effect and safety of different doses of atorvastatin in treating patients with coronary heart disease and carotid plaque. Methods Eighty-one patients with coronary heart disease and carotid plaque hospitalized in Laiyuan County Hospital from January 2010 to March 2011 were selected and randomly divided into two groups according to random number table.40 patients in control group were treated with atorvastatin 10 mg/d,while 41 patients in observation group were received atorvastatin 20 mg/d.The efficacy and safety of the therapy were compared and analyzed between the two groups. Results After the treatment,the total cholesterol(TC),triglyceride (TG),and low-density lipoprotein cholesterol(LDL-C) were significantly decreased in the two groups,those in observation group were significantly more reduced,and the differences were statistically significant between the two groups(P<0.05).After the treatment,the common carotid artery intima-media thickness(IMT) and plaque area were significantly reduced in the two groups,and more obvious changes were found in observation group;there were statistically significant differences between the two groups(P<0.05).No serious adverse events occurred in the two groups. Conclusion Atorvastatin 20 mg/d shows better clinical efficacy and high safety in the treatment of patients with coronary heart disease and carotid plaque,which can significantly improve blood lipid levels and reduce carotid artery plaque.And it is one of the preferred therapeutic schemes.